Amphion Innovations plc
Notice of Intention to List on NASDAQ
by Motif Bio plc
London and New York, 13 July 2016 - Amphion Innovations, a developer of medical, life science, and technology businesses, is pleased to announce that Partner Company, Motif Bio plc (AIM: MTFB), has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed public offering (the “Offering”) of American Depositary Shares (“ADSs”). Motif Bio has also applied to have its ADSs listed on the NASDAQ Global Select Market under the ticker symbol “MTFB”. Following completion of the offering of the ADSs, Motif Bio’s ordinary shares will continue to trade on the AIM market of the London Stock Exchange. The number of ADSs to be offered and the price per ADS for the Offering have not yet been determined. As of the date of this announcement, Motif has not yet set a definite timetable or decided on further details of the potential Offering, and there can be no assurance that the potential Offering will be completed.
Amphion currently owns 26.08% of Motif Bio plc.
For further information please contact
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes (Corporate Broking)
+44 (0)20 7382 1100
Plumtree Capital Limited (Financial Adviser)
+44 (0)20 7183 2493
+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.